Boostimmune Secures Broad Japanese Patent for Antibody Technology Targeting Tumor Microenvironment Immunosuppression
Boostimmune has been granted a Japanese patent covering antibodies that inhibit translationally controlled tumor protein (TCTP) released from dead tumor cells, suppressing myeloid-derived suppressor cell (MDSC) accumulation in the tumor microenvironment. The patent claims are defined by function and therapeutic applic…